Send to

Choose Destination
Cell Regen (Lond). 2018 Nov 2;7(2):40-44. doi: 10.1016/ eCollection 2018 Dec.

Approaches for generation of anti-leukemia specific T cells.

Jin Z1,2, Xu L1,3, Li Y1,3.

Author information

Key Laboratory for Regenerative Medicine of Ministry of Education; Institute of Hematology, School of Medicine; Jinan University, Guangzhou, 510632, China.
Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou, 510632, China.
Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.


As three decades ago, it was reported that adoptive T cell immunotherapy by infusion of autologous tumor infiltrating lymphocytes (TILs) mediated objective cancer regression in patients with metastatic melanoma. A new era of T cell immunotherapy arose since the improvement and clinical use of anti-CD19 chimeric antigen receptor T cells (CAR-T) for the treatment of refractory and relapsed B lymphocyte leukemia. However, several challenges and difficulties remain on the way to reach generic and effective T cell immunotherapy, including lacking a generic method for generating anti-leukemia-specific T cells from every patient. Here, we summarize the current methods of generating anti-leukemia-specific T cells, and the promising approaches in the future.


ACT, adoptive cellular immunotherapy; APL, promyelocytic leukemia; Anti-leukemia T cell; B-ALL, cell acute lymphoblastic leukemia; CAR-T; CAR-T, chimeric antigen receptor T cells; CML, chronic myelogenous leukemia; CR, complete remission; CTLs, cytotoxic T cells; DLI, donor lymphocyte infusion; FLT3-ITD, FLT3 internal tandem duplication; GVHD, graft-versus-host disease; GVL, graft-versus-leukemia; HLA, human leukocyte antigen; HPCs, hematopoietic progenitor cells; IL-2, interleukin-2; Ig, immunoglobulin; T cell immunotherapy; T cell reprogramming; TAA, tumor-associated antigen; TCR-T; TCR-T, TCR gene-modified T cell; TIL, infiltrating lymphocytes; TKI, tyrosine kinase inhibitor; WT1, Wilm's tumor antigen 1; allo-HSCT, allogeneic hematopoietic stem cell transplantation; hESC, human embryonic stem cell; iPSCs, induced pluripotent stem cells; iTs, induced functional T cells; scFv, single-chain variable fragment

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center